Study of IBI363 in Patients with Advanced First-line Gastric Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of IBI363 in Patients with Advanced First-line Gastric Cancer — Stella

Recruiting

Back to IBI363 + Chemotherapy trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Zhejiang Cancer Hospital, Hangzhou, Zhejiang

Key details

Phase

Early testing

Sponsor

Xiangdong Cheng

Enrollment target

~40 participants

Started

October 2024

Primary completion

June 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov